BMY•benzinga•
Bristol Myers Inks $11 Billion Licensing Pact With BioNTech For Bispecific Cancer Drug
Summary
BioNTech and Bristol Myers Squibb will co-develop BNT327 for solid tumors in a $1.5 billion deal with potential milestones totaling up to $7.6 billion.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 2, 2025 by benzinga